The Obesity Drug Graveyard

Luqman Rauf
Jun 12
5 min read

A Century of Hype, Harm, and Withdrawal

Before GLP-1 agonists, there was a long line of "miracle" drugs that promised effortless weight loss. Each was hailed as a breakthrough. Each ended in disaster.

This is the pattern that has repeated itself for nearly a century. Every time we try to outsmart the body's intelligence, history proves that we pay the ultimate price.

The 1930s: The First Casualty

DNP (2,4-Dinitrophenol) — 1933

DNP was borrowed from munitions manufacturing. It worked by uncoupling oxidative phosphorylation — forcing the body to burn energy as heat instead of producing ATP. Weight loss was rapid.

But patients were literally cooked to death from the inside. Hyperthermia, cataracts, neuropathy, and fatal overdoses mounted. By 1938, the FDA banned it as "extremely dangerous and not fit for human consumption."

Body count: Dozens of deaths. Cataracts in survivors. No antidote was ever developed.

The 1940s–1960s: The Stimulant Era

Amphetamines (Benzedrine) — 1930s–1940s

Amphetamines suppressed appetite by releasing dopamine and norepinephrine. They were effective but highly addictive. Patients developed tolerance, then dependence, then psychosis. By the late 1950s, regulators had restricted their use.

Methamphetamine — 1947

Approved for obesity. More addictive than standard amphetamines. Withdrawn as addiction and psychiatric complications became undeniable.

Rainbow Pills — 1940s–1960s

These were the original "cocktail" approach: brightly coloured capsules combining amphetamines, thyroid hormone, diuretics, laxatives, digitalis, barbiturates, and sometimes corticosteroids. The pills were marketed directly to physicians, who then sold them to patients as "personalised" weight loss regimens.

They caused arrhythmias, strokes, organ failure, and death. By 1968, the FDA banned them outright.

Phentermine — 1959

Still in use today as a short-term aid. It is an amphetamine congener — safer than methamphetamine but still carries risks of tachycardia, insomnia, and dependence.

The 1970s–1980s: More Failures

Aminorex — 1971

A sympathomimetic appetite suppressant. Withdrawn within a year of marketing when linked to pulmonary hypertension — a rare and often fatal lung disease.

Human Chorionic Gonadotropin (HCG) — 1961–1990

Promoted as a weight loss aid based on a flawed theory. Multiple studies proved it was ineffective compared to placebo. Disapproved.

Gelatin-based very low-calorie diet — 1985

Not a drug, but a liquid protein diet. Linked to cardiovascular deaths (torsade de pointes) due to cardiac muscle wasting. Withdrawn.

Fluoxetine (Prozac) — 1991–1995

Tested for weight loss due to its serotonin effects. Patients lost weight initially, then regained while still on the drug. Discontinued for this indication.

β-3 Agonists — 1985–1998

Designed to increase thermogenesis. Limited effect and increased heart rate. Abandoned.

The 1990s: The Fen-Phen Catastrophe

Fen-Phen (Fenfluramine + Phentermine) — 1990s

The combination of fenfluramine and phentermine was the most successful weight loss drug of its era. Prescriptions soared to more than 18 million annually. Patients lost substantial weight. It seemed like the breakthrough the world had been waiting for.

Then the nightmare began.

In 1997, the New England Journal of Medicine reported that fenfluramine caused valvular heart disease — damage to heart valves that required surgery or led to heart failure. It was also linked to primary pulmonary hypertension.

The FDA withdrew fenfluramine in 1997. The manufacturer, Wyeth, faced 175,000 claims and set aside $21 billion in settlements.

Patients like Phyllis Hardy and Marcella Sherrod — women in their 30s and 40s who took the drug for a few months — developed irreversible heart valve damage. Sherrod died before her scheduled valve replacement surgery.

Legacy: The largest pharmaceutical liability case in history. It hardened regulatory caution and deepened payer skepticism for decades.

The 2000s: More Withdrawals

Phenylpropanolamine (PPA) — 1998

A sympathomimetic used in appetite suppressants and cold remedies. A Yale study found it caused haemorrhagic stroke in young women. Estimated 200–500 strokes per year. Withdrawn from the market.

Ephedra / Ephedrine / Ma Huang — 2003

A stimulant sold in dietary supplements. Popular for weight loss and energy. Caused heart attacks, strokes, and sudden death. The FDA banned it in 2004.

Rimonabant (Acomplia) — 2006

A novel cannabinoid receptor blocker. Approved in Europe but never in the United States. It caused depression, anxiety, and suicidal thoughts at rates of up to 10% of patients.

Withdrawn in 2008–2009. Psychiatric adverse events accounted for half of all early terminations in clinical trials.

Sibutramine (Meridia) — 1997–2010

A serotonin-norepinephrine reuptake inhibitor approved for obesity. Withdrawn in 2010 after the SCOUT trial (10,000 patients, up to 6 years) showed an increased risk of heart attack and stroke in patients with pre-existing cardiovascular disease.

Lorcaserin (Belviq) — 2012

A serotonin 2C agonist approved for weight loss. Withdrawn in 2020 after long-term studies showed an increased risk of cancer (pancreatic, colorectal, lung).

The 2010s–2020s: The GLP-1 Era

Liraglutide (Saxenda) — 2014

The first GLP-1 agonist approved for obesity. Patients lost 5–10% of body weight — an improvement over earlier drugs. But it required daily injections and cost more than $1,000 per month. With limited insurance coverage, uptake was sparse.

Semaglutide (Wegovy) — 2021

The current blockbuster. Patients lose 15–20% of body weight. Sales have reached tens of billions annually. It is hailed as a breakthrough.

But as documented elsewhere in this work, the long-term metabolic costs — muscle loss, nutrient depletion, metabolic inflexibility, and post-drug rebound — remain unmeasured in the short-term trials that secured its approval.

The Recurring Pattern

Decade	Drug	Mechanism	Reason for Withdrawal
1930s	DNP	Uncouples oxidative phosphorylation	Hyperthermia, cataracts, death
1940s–60s	Amphetamines, Methamphetamine	Central nervous system stimulants	Addiction, psychosis, cardiovascular toxicity
1940s–60s	Rainbow Pills	Cocktails of amphetamines, thyroid, diuretics, digitalis, barbiturates	Arrhythmias, strokes, organ failure, death
1970s	Aminorex	Sympathomimetic	Pulmonary hypertension
1990s	Fen-Phen	Serotonergic + sympathomimetic	Heart valve damage, pulmonary hypertension
2000s	Ephedra	Sympathomimetic	Heart attacks, strokes, sudden death
2000s	Rimonabant	Cannabinoid receptor blocker	Depression, suicidality
2010s	Sibutramine	SNRI	Heart attack, stroke
2020s	Lorcaserin	Serotonin 2C agonist	Cancer

The Common Thread

Every drug on this list had three things in common:

Short-term efficacy — they worked for weight loss in the first 1–2 years
Long-term harm — side effects that took years to manifest
Incomplete trials — the studies did not measure what ultimately killed the drug

The trials measured weight loss. They did not measure heart valves (Fen-Phen). They did not measure psychiatric outcomes (Rimonabant). They did not measure long-term cardiovascular events (Sibutramine). They did not measure cancer (Lorcaserin).

And with GLP-1 agonists, they are not measuring muscle loss, nutrient depletion, metabolic inflexibility, or post-drug rebound.

The Closing

"For nearly a century, every 'miracle' weight loss drug has followed the same arc: rapid adoption based on short-term weight loss, followed by withdrawal when the long-term harms emerge — cataracts, addiction, heart valve destruction, pulmonary hypertension, stroke, suicide, or cancer. The only thing that has changed is the name of the drug and the nature of the harm. The pattern is the same.

Every time we try to outsmart the body's intelligence — to override its evolved metabolic wisdom with a blunt pharmaceutical signal — history has proven that we pay the ultimate price. The body adapts, resists, or breaks. Sometimes quietly. Sometimes catastrophically. But always, eventually.

GLP-1 agonists will not be the exception. They will be the latest chapter in a very old story."